Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension?
Biaggioni
Italo
I
Department of Medicine, Vanderbilt University, Nashville, TN 37232, USA. Italo.biaggioni@vanderbilt.edu
D018674:Adrenergic Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000503:physiopathology* / Q000628:therapy*; D009765:Obesity / Q000150:complications* / Q000628:therapy; D013564:Sympathetic Nervous System / Q000503:physiopathology*; D013565:Sympatholytics / Q000627:therapeutic use; D015431:Weight Loss
D018674:Adrenergic Antagonists; D000959:Antihypertensive Agents; D013565:Sympatholytics